With 78 patents held between 2002 and 2022, Johnson & Johnson holds the most number of Cell & Gene Therapy patents in the Chemicals sector in the Asia-Pacific region, of which 33.3% was contributed by Johnson & Johnson Vision Care Inc.
The second largest number of patents were held by AbbVie Inc with 57 Cell & Gene Therapy patents, of which 40.4% was contributed by Allergan Inc. The third largest number of patents were held by The Scripps Research Institute with 50 Cell & Gene Therapy patents. The fourth largest number of patents were held by Novartis AG with 50 Cell & Gene Therapy patents. The fifth largest number of patents were held by Alcon Inc with 45 Cell & Gene Therapy patents.
The top five patents holders, i.e., Johnson & Johnson, AbbVie Inc, The Scripps Research Institute, Novartis AG, and Alcon Inc, together held 280 Cell & Gene Therapy patents during the period.
Taiwan
Germany
China
United States of America
South Korea
South Korea
Saudi Arabia
China
United Kingdom
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer